Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 221

1.

Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease.

Date AA, Halpert G, Babu T, Ortiz J, Kanvinde P, Dimitrion P, Narayan J, Zierden H, Betageri K, Musmanno O, Wiegand H, Huang X, Gumber S, Hanes J, Ensign LM.

Biomaterials. 2018 Dec;185:97-105. doi: 10.1016/j.biomaterials.2018.09.005. Epub 2018 Sep 7.

PMID:
30236840
2.

Midazolam and Dexmedetomidine Affect Neuroglioma and Lung Carcinoma Cell Biology In Vitro and In Vivo.

Wang C, Datoo T, Zhao H, Wu L, Date A, Jiang C, Sanders RD, Wang G, Bevan C, Ma D.

Anesthesiology. 2018 Nov;129(5):1000-1014. doi: 10.1097/ALN.0000000000002401.

PMID:
30157038
3.

Development of rectal enema as microbicide (DREAM): Preclinical progressive selection of a tenofovir prodrug enema.

Hoang T, Date AA, Ortiz JO, Young TW, Bensouda S, Xiao P, Marzinke M, Rohan L, Fuchs EJ, Hendrix C, Gumber S, Villinger F, Cone RA, Hanes J, Ensign LM.

Eur J Pharm Biopharm. 2018 May 24. pii: S0939-6411(18)30476-4. doi: 10.1016/j.ejpb.2018.05.030. [Epub ahead of print]

PMID:
29802984
4.

Higher-than-expected prevalence of non-tuberculous mycobacteria in HIV setting in Botswana: Implications for diagnostic algorithms using Xpert MTB/RIF assay.

Agizew T, Basotli J, Alexander H, Boyd R, Letsibogo G, Auld A, Nyirenda S, Tedla Z, Mathoma A, Mathebula U, Pals S, Date A, Finlay A.

PLoS One. 2017 Dec 22;12(12):e0189981. doi: 10.1371/journal.pone.0189981. eCollection 2017.

5.

Cost-effective Decisions in Managing Silent Common Bile Duct Stones Should Include All the Management Options to Help Decision Makers.

Date A, Date RS.

Ann Surg. 2017 Dec;266(6):e89-e90. doi: 10.1097/SLA.0000000000001714. No abstract available.

PMID:
29137002
6.

Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection.

Xiao P, Gumber S, Marzinke MA, Date AA, Hoang T, Hanes J, Ensign LM, Wang L, Rohan L, Fuchs EJ, Hendrix C, Villinger F.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01644-17. doi: 10.1128/AAC.01644-17. Print 2018 Jan.

7.

Influence of region-of-interest determination on measurement of signal-to-noise ratio in liver on PET images.

Amakusa S, Matsuoka K, Kawano M, Hasegawa K, Ouchida M, Date A, Yoshida T, Sasaki M.

Ann Nucl Med. 2018 Jan;32(1):1-6. doi: 10.1007/s12149-017-1215-y. Epub 2017 Oct 20.

PMID:
29058224
8.

Peripheral clinic versus centralized laboratory-based Xpert MTB/RIF performance: Experience gained from a pragmatic, stepped-wedge trial in Botswana.

Agizew T, Boyd R, Ndwapi N, Auld A, Basotli J, Nyirenda S, Tedla Z, Mathoma A, Mathebula U, Lesedi C, Pals S, Date A, Alexander H, Kuebrich T, Finlay A.

PLoS One. 2017 Aug 17;12(8):e0183237. doi: 10.1371/journal.pone.0183237. eCollection 2017.

9.

Preclinical Evaluation of Intravesical Cisplatin Nanoparticles for Non-Muscle-Invasive Bladder Cancer.

Kates M, Date A, Yoshida T, Afzal U, Kanvinde P, Babu T, Sopko NA, Matsui H, Hahn NM, McConkey DJ, Baras A, Hanes J, Ensign L, Bivalacqua TJ.

Clin Cancer Res. 2017 Nov 1;23(21):6592-6601. doi: 10.1158/1078-0432.CCR-17-1082. Epub 2017 Aug 14.

PMID:
28808039
10.

Rolling Out Xpert® MTB/RIF for TB Detection in HIV-Infected Populations:An Opportunity for Systems Strengthening.

Pathmanathan I, Date A, Coggin WL, Nkengasong J, Piatek AS, Alexander H.

Afr J Lab Med. 2017 Mar 31;6(2). pii: a460. doi: 10.4102/ajlm.v6i2.460.

11.

Knowledge of Human Immunodeficiency Virus Status and Seropositivity After a Recently Negative Test in Malawi.

Pathmanathan I, Lederer P, Shiraishi RW, Wadonda-Kabondo N, Date A, Matatiyo B, Dokubo EK.

Open Forum Infect Dis. 2016 Dec 15;4(1):ofw231. doi: 10.1093/ofid/ofw231. eCollection 2017 Winter.

12.

MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound.

Timbie KF, Afzal U, Date A, Zhang C, Song J, Wilson Miller G, Suk JS, Hanes J, Price RJ.

J Control Release. 2017 Oct 10;263:120-131. doi: 10.1016/j.jconrel.2017.03.017. Epub 2017 Mar 11.

13.

Local enema treatment to inhibit FOLH1/GCPII as a novel therapy for inflammatory bowel disease.

Date AA, Rais R, Babu T, Ortiz J, Kanvinde P, Thomas AG, Zimmermann SC, Gadiano AJ, Halpert G, Slusher BS, Ensign LM.

J Control Release. 2017 Oct 10;263:132-138. doi: 10.1016/j.jconrel.2017.01.036. Epub 2017 Jan 31.

14.

Optimization of Recovery and Analysis of RNA in Sorted Cells in mRNA Quantification After Fluorescence-activated Cell Sorting.

Maeda T, Date A, Watanabe M, Hidaka Y, Iwatani Y, Takano T.

Ann Clin Lab Sci. 2016 Dec;46(6):571-577.

PMID:
27993868
15.

Implementation of a pragmatic, stepped-wedge cluster randomized trial to evaluate impact of Botswana's Xpert MTB/RIF diagnostic algorithm on TB diagnostic sensitivity and early antiretroviral therapy mortality.

Auld AF, Agizew T, Pals S, Finlay A, Ndwapi N, Boyd R, Alexander H, Mathoma A, Basotli J, Gwebe-Nyirenda S, Shepherd J, Ellerbrock TV, Date A.

BMC Infect Dis. 2016 Oct 26;16(1):606.

16.

Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.

Date AA, Hanes J, Ensign LM.

J Control Release. 2016 Oct 28;240:504-526. doi: 10.1016/j.jconrel.2016.06.016. Epub 2016 Jun 9. Review.

17.

Energetics of nonpolar and polar compounds in cationic, anionic, and nonionic micelles studied by all-atom molecular dynamics simulation combined with a theory of solutions.

Date A, Ishizuka R, Matubayasi N.

Phys Chem Chem Phys. 2016 May 21;18(19):13223-31. doi: 10.1039/c6cp01834c. Epub 2016 Apr 27.

PMID:
27117093
18.

Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.

Destache CJ, Mandal S, Yuan Z, Kang G, Date AA, Lu W, Shibata A, Pham R, Bruck P, Rezich M, Zhou Y, Vivekanandan R, Fletcher CV, Li Q.

Antimicrob Agents Chemother. 2016 May 23;60(6):3633-9. doi: 10.1128/AAC.00450-16. Print 2016 Jun.

19.

Phlorizin, an Active Ingredient of Eleutherococcus senticosus, Increases Proliferative Potential of Keratinocytes with Inhibition of MiR135b and Increased Expression of Type IV Collagen.

Choi HR, Nam KM, Lee HS, Yang SH, Kim YS, Lee J, Date A, Toyama K, Park KC.

Oxid Med Cell Longev. 2016;2016:3859721. doi: 10.1155/2016/3859721. Epub 2016 Mar 6.

20.

Defective heat moisture exchange filter causing 'block' in anaesthesia breathing circuit.

Kapoor H, Date A, Gujarkar K, Wagh H.

Indian J Anaesth. 2016 Jan;60(1):66-8. doi: 10.4103/0019-5049.174802. No abstract available.

21.
22.

Modular protein switches derived from antibody mimetic proteins.

Nicholes N, Date A, Beaujean P, Hauk P, Kanwar M, Ostermeier M.

Protein Eng Des Sel. 2016 Feb;29(2):77-85. doi: 10.1093/protein/gzv062. Epub 2015 Dec 5.

23.

Expanding human immunodeficiency virus testing and counseling to reach tuberculosis clients' partners and families.

Courtenay-Quirk C, Date A, Bachanas P, Baggaley R, Getahun H, Nelson L, Granich R.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1414-6. doi: 10.5588/ijtld.15.0007.

24.

Natural polyphenols: potential in the prevention of sexually transmitted viral infections.

Date AA, Destache CJ.

Drug Discov Today. 2016 Feb;21(2):333-41. doi: 10.1016/j.drudis.2015.10.019. Epub 2015 Nov 4. Review.

PMID:
26546859
25.

Correction: Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.

Kovarova M, Council OD, Date AA, Long JM, Nochi T, Belshan M, Shibata A, Vincent H, Baker CE, Thayer WO, Kraus G, Lachaud-Durand S, Williams P, Destache CJ, Garcia JV.

PLoS Pathog. 2015 Oct 16;11(10):e1005170. doi: 10.1371/journal.ppat.1005170. eCollection 2015 Oct. No abstract available.

26.

Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.

Date AA, Shibata A, McMullen E, La Bruzzo K, Bruck P, Belshan M, Zhou Y, Destache CJ.

J Biomed Nanotechnol. 2015 Mar;11(3):416-27.

27.

Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission.

Kovarova M, Council OD, Date AA, Long JM, Nochi T, Belshan M, Shibata A, Vincent H, Baker CE, Thayer WO, Kraus G, Lachaud-Durand S, Williams P, Destache CJ, Garcia JV.

PLoS Pathog. 2015 Aug 13;11(8):e1005075. doi: 10.1371/journal.ppat.1005075. eCollection 2015 Aug. Erratum in: PLoS Pathog. 2015 Oct;11(10):e1005170. Nochii, Tomonori [corrected to Nochi, Tomonori].

28.

Cationic nanoemulsions as potential carriers for intracellular delivery.

Khachane PV, Jain AS, Dhawan VV, Joshi GV, Date AA, Mulherkar R, Nagarsenker MS.

Saudi Pharm J. 2015 Apr;23(2):188-94. doi: 10.1016/j.jsps.2014.07.007. Epub 2014 Jul 18.

29.

Celecoxib nanosuspension: single-step fabrication using a modified nanoprecipitation method and in vivo evaluation.

Malkani A, Date AA, Hegde D.

Drug Deliv Transl Res. 2014 Aug;4(4):365-76. doi: 10.1007/s13346-014-0201-3.

PMID:
25787068
30.

Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.

Briggs MA, Emerson C, Modi S, Taylor NK, Date A.

J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S297-305. doi: 10.1097/QAI.0000000000000497. Review.

PMID:
25768869
31.

TB screening among people living with HIV/AIDS in resource-limited settings.

Date A, Modi S.

J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3:S270-3. doi: 10.1097/QAI.0000000000000485. Review.

PMID:
25768866
32.

Characterization of monobody scaffold interactions with ligand via force spectroscopy and steered molecular dynamics.

Cheung LS, Shea DJ, Nicholes N, Date A, Ostermeier M, Konstantopoulos K.

Sci Rep. 2015 Feb 4;5:8247. doi: 10.1038/srep08247.

33.

TB-HAART trial.

Lederer P, Briggs M, Hassani AS, Date A.

Lancet Infect Dis. 2015 Jan;15(1):14. doi: 10.1016/S1473-3099(14)71028-X. No abstract available.

PMID:
25541162
34.

Provision of antiretroviral therapy for HIV-positive TB patients--19 countries, sub-Saharan Africa, 2009-2013.

Dokubo EK, Baddeley A, Pathmanathan I, Coggin W, Firth J, Getahun H, Kaplan J, Date A.

MMWR Morb Mortal Wkly Rep. 2014 Nov 28;63(47):1104-7.

35.

Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates.

Date AA, Shibata A, Bruck P, Destache CJ.

Biomed Chromatogr. 2015 May;29(5):709-15. doi: 10.1002/bmc.3346. Epub 2014 Oct 9.

36.

Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV.

Gupta S, Abimbola T, Date A, Suthar AB, Bennett R, Sangrujee N, Granich R.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1159-65. doi: 10.5588/ijtld.13.0571.

37.

Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries.

Gupta S, Granich R, Date A, Lepere P, Hersh B, Gouws E, Samb B.

Int J Tuberc Lung Dis. 2014 Oct;18(10):1149-58. doi: 10.5588/ijtld.13.0889. Review.

PMID:
25216827
38.

Unusual occurrence of missing central incisor: a case report.

Date AS.

Gen Dent. 2014 May-Jun;62(3):54-5.

PMID:
24784515
39.

An improved protocol for mRNA quantification after fluorescence-activated cell sorting with an increased signal to noise ratio in flow cytometry.

Date A, Maeda T, Watanabe M, Hidaka Y, Iwatani Y, Takano T.

Mol Biotechnol. 2014 Jul;56(7):591-8. doi: 10.1007/s12033-014-9733-5.

PMID:
24510221
40.

The Identification of Pompe Disease Mutations in Archival Tissues and Development of a Rapid Molecular-based Test.

Alansari A, Al-Rawahi S, Ba-Omar T, Al-Nabhani M, Date A.

Sultan Qaboos Univ Med J. 2013 Nov;13(4):502-9. Epub 2013 Nov 8.

41.

Anti-tuberculosis drug resistance among new and previously treated sputum smear-positive tuberculosis patients in Uganda: results of the first national survey.

Lukoye D, Adatu F, Musisi K, Kasule GW, Were W, Odeke R, Kalamya JN, Awor A, Date A, Joloba ML.

PLoS One. 2013 Aug 1;8(8):e70763. doi: 10.1371/journal.pone.0070763. Print 2013.

42.

Phloridzin isolated from Acanthopanax senticosus promotes proliferation of α6 integrin (CD 49f) and β1 integrin (CD29) enriched for a primary keratinocyte population through the ERK-mediated mTOR pathway.

Lee J, Jung E, Kim YS, Park D, Toyama K, Date A, Lee J.

Arch Dermatol Res. 2013 Oct;305(8):747-54. doi: 10.1007/s00403-013-1398-6. Epub 2013 Aug 3.

PMID:
23912479
43.

A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Date AA, Destache CJ.

Biomaterials. 2013 Aug;34(26):6202-28. doi: 10.1016/j.biomaterials.2013.05.012. Epub 2013 May 28. Review.

44.

Human keratinocyte caspase-14 expression is altered in human epidermal 3D models by dexamethasone and by natural products used in cosmetics.

Kataoka S, Hattori K, Date A, Tamura H.

Arch Dermatol Res. 2013 Oct;305(8):683-9. doi: 10.1007/s00403-013-1359-0. Epub 2013 Apr 21.

PMID:
23604963
45.

Protein switch engineering by domain insertion.

Kanwar M, Wright RC, Date A, Tullman J, Ostermeier M.

Methods Enzymol. 2013;523:369-88. doi: 10.1016/B978-0-12-394292-0.00017-5.

46.

Dual colour cw mode-locking through soft aperture based on second order cascaded nonlinearity.

Mukhopadhyay S, Mondal S, Singh SP, Date A, Hussain K, Datta PK.

Opt Express. 2013 Jan 14;21(1):454-62. doi: 10.1364/OE.21.000454.

PMID:
23388939
47.

Polymeric nanoparticles containing combination antiretroviral drugs for HIV type 1 treatment.

Shibata A, McMullen E, Pham A, Belshan M, Sanford B, Zhou Y, Goede M, Date AA, Destache CJ.

AIDS Res Hum Retroviruses. 2013 May;29(5):746-54. doi: 10.1089/AID.2012.0301. Epub 2013 Feb 1. Erratum in: AIDS Res Hum Retroviruses. 2013 Jul;29(7):1095. Date, Abjijit A [corrected to Date, Abhijit A].

48.

Changes in the circadian rhythm of mRNA expression for µ-opioid receptors in the periaqueductal gray under a neuropathic pain-like state.

Takada T, Yamashita A, Date A, Yanase M, Suhara Y, Hamada A, Sakai H, Ikegami D, Iseki M, Inada E, Narita M.

Synapse. 2013 May;67(5):216-23. doi: 10.1002/syn.21633. Epub 2013 Feb 8.

PMID:
23280810
49.

Aerva lanata (Polpala): Its effects on the structure and function of the urinary tract.

Gunatilake M, Lokuhetty MD, Bartholameuz NA, Edirisuriye DT, Kularatne MU, Date A.

Pharmacognosy Res. 2012 Oct;4(4):181-8. doi: 10.4103/0974-8490.102259.

50.

Coherent backscattering of ultracold atoms.

Jendrzejewski F, Müller K, Richard J, Date A, Plisson T, Bouyer P, Aspect A, Josse V.

Phys Rev Lett. 2012 Nov 9;109(19):195302. Epub 2012 Nov 5.

PMID:
23215395

Supplemental Content

Support Center